Roche have announced that they have entered into an agreement with Ibex Medical Analytics, a global leader in artificial intelligence (AI)-based cancer diagnostics.
Under the agreement, the companies will jointly develop an embedded image analysis workflow for pathologists to seamlessly access Ibex's AI algorithms, insights, and decision support tools using NAVIFY Digital Pathology, the cloud version of Roche's uPath enterprise software. Collaborations with leading AI companies like Ibex are made possible through Roche's Digital Pathology Open Environment, which allows pathologists to securely access third-party AI-powered technology alongside Roche's growing menu of AI-based image analysis tools.
Ibex's Galen platform recently received Breakthrough Device Designation by the U.S. Food and Drug Administration (US FDA) and CE mark in Europe for breast and prostate cancer detection in multiple workflows. Through this alliance, customers using Roche Digital Pathology will gain access to Ibex's innovative tools, such as algorithms that analyse prostate and breast biopsies, in addition to the AI tools already provided by Roche.
The clinical-grade AI algorithms and digital workflows included in this expanded menu of tools is expected to enable pathologists to provide accurate, efficient and timely diagnoses for their patients and support them in the detection and grading of cancer, identification of important non-cancerous features, case reporting and more.
